Regulated markets hold key for Alembic as it eyes its first ANDA approval
This article was originally published in Scrip
Executive Summary
The Indian company, Alembic, expects its own active pharmaceutical ingredient (API) and ANDA projects in regulated markets to drive future growth. The company, which expects to receive its first ANDA approval in the US within the next quarter or so, has already firmed up distribution alliances in the US and Europe as some of its projects bear fruit there.